ALPHARETTA, Ga.–(BUSINESS
WIRE)–SANUWAVE Health, Inc. today announced that the U.S. Patent and
Trademark Office (USPTO) has issued the Company patent number 8,092,401, titled
“Method and Apparatus for Producing Shock Waves for Medical Applications.” The
patent has a term extending to February 2027 and relates to a new method of
producing shock waves utilizing a mechanically pressurized fluid.

In conventional methods to produce an acoustic shock wave,
the acoustic wave is triggered by an electrical impulse. By contrast, the novel
method presented in this patent is mechanical and comprises oscillating high
pressure generated in the encapsulated fluid within the treatment applicator,
which is used to produce focused acoustic shock waves. This innovation may
create efficiencies in design, manufacture and usability of the Companys
Pulsed Acoustic Cellular Expression (PACE®) technology and allows for unique
device configurations and clinical applications that were not previously
possible.

“We are pleased to be awarded this new patent as it has
potential to be a significant asset in our product development efforts,” stated
Christopher M. Cashman, President and CEO of SANUWAVE. “This method of
producing acoustic shock waves is different from the electrohydraulic method we
use in our current products, and it could give rise to new clinical indications
and alternative regulatory pathways for future product offerings.”

About PACE

PACE, defined as Pulsed Acoustic Cellular Expression, delivers high-energy
acoustic pressure waves in the shock wave spectrum to produce compressive and
tensile stresses on cells and tissue structures which are designed to promote
angiogenic and positive inflammatory responses, and quickly initiate the
healing cascade. This is thought to result in microcirculatory improvement,
including increased perfusion and blood vessel widening (arteriogenesis), the
production of angiogenic growth factors, enhanced new blood vessel formation
(angiogenesis) and the subsequent regeneration of tissue such as skin,
musculoskeletal and vascular structures. PACE procedures trigger the initiation
of an accelerated inflammatory response that speeds wounds into proliferation
phases of healing and subsequently returns a chronic condition to an acute
condition to help reinitiate the bodys own healing response.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (www.sanuwave.com) is an emerging regenerative medicine
company focused on the development and commercialization of noninvasive,
biological response activating devices for the repair and regeneration of
tissue, musculoskeletal and vascular structures. SANUWAVEs portfolio of
products and product candidates activate biologic signaling and angiogenic
responses, including new vascularization and microcirculatory improvement,
helping to restore the bodys normal healing processes and regeneration.
SANUWAVE intends to apply its PACE technology in wound healing,
orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product
candidate for the global wound care market, dermaPACE®, is CE marked for
treatment of the skin and subcutaneous soft tissue and recently completed its
pivotal Phase III, Investigational Device Exemption (IDE) clinical trial in the
U.S. for the treatment of diabetic foot ulcers. SANUWAVE researches, designs,
manufactures, markets and services its products worldwide, and believes it has
demonstrated that its technology is safe and effective in stimulating healing
in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral
epicondylitis) through its U.S. Class III PMA approved Ossatron® device, as
well as stimulating bone and chronic tendonitis regeneration in the
musculoskeletal environment through the utilization of its Ossatron, Evotron™
and orthoPACE® devices in Europe.

Posted by Sean Fenske, Editor-in-Chief, MDT